A study to evaluate exposure to selected smoke constituents when using novel heated tobacco product DT3.0a

A study to evaluate exposure to selected smoke constituents in healthy adult smokers using novel heated tobacco product DT3.0a for 5 days under clinical confinement - A study to evaluate exposure to selected smoke constituents in healthy adult smokers using novel heated tobacco product DT3.0a for 5 days under clinical confinement

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000045304

Enrollment

Registered

2021-09-01

Start date

2021-09-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smokers

Interventions

&lt

Non-menthol Smokers&gt

Use of subject&#39

s own brand cigarette for 2 days (clinical confinement)- Use of heated tobacco product DT3.0a for 5 days (clinical confinement) &lt

s own brand cigarette for 2 days (clinical confinement) - Use of heated tobacco product THS for 5 days (clinical confinement) &lt

s own brand cigarette for 2 days (clinical confinement) - Continued use of subject&#39

s own brand cigarette for 5 days (clinical confinement) &lt

s own brand cigarette for 2 days (clinical confinement) - Abstinence from smoking for 5 days (clinical confinement) &lt

Menthol Smokers&gt

s own brand cigarette for 2 days (clinical confinement) - Use of heated tobacco product mDT3.0a for 5 days (clinical confinement) &lt

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Subjects who sign the study-specific consent form - Subjects who are confirmed to be in good health from all of the inspection results - Subjects who smoke commercial cigarettes more than one year etc.

Exclusion criteria

Exclusion criteria: - Subjects who have used tobacco products other than commercial cigarettes (i.e. heated tobacco products, hand-rolled cigarettes, cigarillos, cigars, pipes, snuff tobacco, chewing tobacco, etc.) within one week before screening - Pregnant or lactating women or women who may be pregnant - Subjects who have positive test result of SARS-CoV-2 test by the time of admission on Day-2 - Employed by the tobacco industries, CRO or clinical facility etc.

Design outcomes

Primary

Measure	Time frame
The difference of biomarkers of exposure to selected smoke constituents between the investigational groups	—

Countries

Japan

Contacts

Public ContactDanting Huangfu

JAPAN TOBACCO INC. Scientific Regulatoly Affairs, Tobacco Business Headquarters

danting.huangfu@jt.com080-1040-2819

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026